Dr. Reddy's Laboratories share news, announcements and annual reports
NSE: DRREDDYBSE: 500124Pharmaceuticals & BiotechnologyMid Cap
Dr. Reddy's Laboratories Limited · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Aug 1986 on BSE, May 2003 on NSE
Last close ₹1,352.00up ₹7.00 (0.52%)BSE ₹1,350.20
Share price at the NSE close on 30 Oct 2026. Previous close ₹1,345.00.
30 Oct: open ₹1,345.00, high ₹1,363.70, low ₹1,345.00
52-week range of traded prices to 30 Oct 2026
₹1,101.00Low, 23 Jul 2026₹1,414.90High, 29 Jun 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,12,849 Cr104th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 40.30
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.91
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.59%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 7.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 6.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.15
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 17,14,05957.9% delivered
Dr. Reddy's Laboratories share news and announcements
1,702 announcements, routine notices left out, newest first. Page 24 of 35.
May 2016
Apr 2016
4 Apr · Regulation 44(3) of SEBI (LODR), Reg., 2015
Mar 2016
Feb 2016
Jan 2016
Dec 2015
Nov 2015
26 Nov · News Verification
Exchange has sought clarification from Dr. Reddy's Laboratories Limited., with respect to recent news item captioned "USFDA note: Dr Reddy's did not have data protection system". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.19 Nov · News Verification
News about Dr. Reddy's Laboratories Limited.The media had reports that "Dr. Reddy's tanks 7% as Lundin Law probes violation of norms, Dr. Reddy has received warning letter from USFDA on Nov 5, probe in DRL concerning possible violation of federal security law".The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Dr. Reddy's Laboratories Limited has vide its letter inter-alia stated, "Dr. Reddy's has always adhered to all disclosure requirements both of the Securities and Exchange Commission (SECs) and Indian Stock Exchanges; including accounting practices as per the International Financial Reporting Standards (IFRS) and the Indian Accounting Standards. The Company has no further comment on what might be advertorial Press releases by law firms and refutes all allegations."19 Nov · News Verification
Exchange has sought clarification from Dr. Reddy's Laboratories Limited, with respect to recent news item captioned "Dr. Reddy's tanks 7% as Lundin Law probes violation of norms, Dr. Reddy has received warning letter from USFDA on Nov 5, probe in DRL concerning possible violation of federal security law". In this regard, the Exchange has advised the Company to provide clarification/confirmation on the news item in detail including the following: Whether you/company are aware of any information that has not been announced to the Exchanges which could explain the aforesaid movement in the trading. The response from the company is awaited.
Oct 2015
Sep 2015
28 Sep · News Verification
News about Dr. Reddy's Laboratories Limited.The media had reports that "Dr Reddy's to buy IP rights for Alchemia drug for $17.5 million".The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company.Dr. Reddy's Laboratories Limited has vide its letter inter-alia stated, "We would like to clarify that the aforementioned news article regarding purchase of IP rights for Alchemia drug at $17.5 million is a transaction in the regular course of the business. We already have an existing technology licensing agreement with Alchemia. Proposed transaction just represents a conversion of the said licensing agreement into a proposed IP ownership structure. At this stage we have only signed a binding term sheet with the party and a definitive agreement has not yet been reached. Further, we believe that the impact of this transaction is not material to our operations, warranting a stock exchange intimation under clause 36 of the Listing Agreement."